GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Days Sales Outstanding

Pluri (PLUR) Days Sales Outstanding : 0.00 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Pluri Days Sales Outstanding?

Pluri's average Accounts Receivable for the three months ended in Dec. 2023 was $0.00 Mil. Pluri's Revenue for the three months ended in Dec. 2023 was $0.11 Mil. Hence, Pluri's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Pluri's Days Sales Outstanding or its related term are showing as below:

PLUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 255.51   Med: 1767.06   Max: 19765.54
Current: 368.07

During the past 13 years, Pluri's highest Days Sales Outstanding was 19765.54. The lowest was 255.51. And the median was 1767.06.

PLUR's Days Sales Outstanding is ranked worse than
91.17% of 895 companies
in the Biotechnology industry
Industry Median: 72.67 vs PLUR: 368.07

Pluri's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.


Pluri Days Sales Outstanding Historical Data

The historical data trend for Pluri's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri Days Sales Outstanding Chart

Pluri Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,532.82 19,765.54 - 1,608.96 836.19

Pluri Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 295.95 608.33 -

Competitive Comparison of Pluri's Days Sales Outstanding

For the Biotechnology subindustry, Pluri's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pluri's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Pluri's Days Sales Outstanding falls into.



Pluri Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Pluri's Days Sales Outstanding for the fiscal year that ended in Jun. 2023 is calculated as

Days Sales Outstanding (A: Jun. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2022 ) + Accounts Receivable (A: Jun. 2023 )) / count ) / Revenue (A: Jun. 2023 )*Days in Period
=( (0.955 + 0.36) / 2 ) / 0.287*365
=0.6575 / 0.287*365
=836.19

Pluri's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0.105*365 / 4
=0 / 0.105*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pluri  (NAS:PLUR) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Pluri Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Pluri's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Pluri (PLUR) Business Description

Traded in Other Exchanges
Address
MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
Executives
Lorne Kenneth Abony director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman officer: Chief Executive Officer 63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership 10 percent owner BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer director 33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun director 9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay officer: Chief Financial Officer ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat director HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram director 24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda officer: Chief Financial Officer MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain director WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi officer: Chief Financial Officer MATAM PARK, BUILDING 05, HAIFA L3 31905

Pluri (PLUR) Headlines

From GuruFocus